Institut Curie


In 1909, Marie Curie founded the Institut Curie as a private foundation dedicated to cancer patient treatment and research. Today, over a century later, the Institut Curie’s three sites are a driving force in the international fight against cancer, and the organization has been recognized as France’s leading cancer research institution.

Leading the World in the Race for a Cure

Institut Curie is committed to hospital care, scientific research, and the sharing of knowledge and preserving of legacy.  With each of these objectives, the private Institut Curie has spent over a century illustrating an unwavering commitment to public interests.  As the leading cancer research center in France, the Institut’s joint researcher and physician teams produce cutting-edge, multidisciplinary innovations in understanding and treating cancer.  Furthermore, it is dedicated to preserving and broadening the reach of this knowledge, so that its impact spreads far beyond the borders of France.  In fact, as of 2015, Institut Curie produced 545 medical and scientific publications, each with a significant impact on the preexisting knowledge of its given field.  It is through this collaborative, technologically advanced research that the organization leaves behind a legacy to improve quality of life not only for current patients, but also to train future researchers and physicians to be best equipped for helping the next generation of patients.

Putting Patients First

Although Institut Curie is a large research institution, it is deeply concerned with patient care, and the interests of patients, in everything that they do. Institut Curie’s Hospital Group develops and provides comprehensive care for over 14,000 cancer patients with the central goal of improving quality of life at every stage of the disease.   

GRoW Support

We became deeply invested in the Institut Curie’s commitment to patient care and innovative research by providing the support for the development of the Translational Research Lab in pediatric oncology, which is led by Dr. Gudrun Schleiermacher. Specifically, the lab integrates practiced medicine with scientific research to better understand, diagnose, and treat neuroblastoma, a tragically complex and common form of childhood cancer. In addition to its focus on neuroblastoma, the laboratory conducts intensive molecular, genetic, and immunological studies of various forms of pediatric solid tumors. In the years since the laboratory’s conception, we have continued our support for the discovery and study of new global treatment methods, as well as a deeper understanding of neuroblastoma recurrence in children.

To learn more, visit Institut Curie



Related Organizations